Pre-made Urtoxazumab benchmark antibody (Whole mAb, anti-E.coli Shiga-like toxin 2 B subunit therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Anti-E.coli Shiga-like toxin 2 B subunit therapeutic antibody (Pre-made Urtoxazumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Urtoxazumab is a humanized monoclonal antibody against diarrhoea caused by Escherichia coli, serotype O121. The drug is designed to bind to a toxin of this bacterium, so that it can be more easily broken down and eliminated from the body.[1][2]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-1040-1mg	1mg	3090
GMP-Bios-INN-1040-10mg	10mg	Inquiry
GMP-Bios-INN-1040-100mg	100mg	Inquiry
GMP-Bios-INN-1040-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Urtoxazumab Biosimilar, Whole Mab: Anti-E.Coli Shiga-Like Toxin 2 B Subunit therapeutic antibody
INN Name	Urtoxazumab
Target	E.coli Shiga-like toxin 2 B subunit
Format	Whole mAb
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Teijin Ltd. (Tokyo Japan)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0